The guideline, in effect for three months, gives access to many molecularly informed indications that NICE previously found not cost-effective or that it hasn't yet reviewed.
Based on cost-effectiveness estimates and a lack of comparison against afatinib, NICE will recommend against using osimertinib for first-line treatment of NSCLC.
The guidance is meant to help provide the pharma industry, researchers, and IRBs with information to facilitate studies of oncology drugs for pediatric patients.
